Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
about
Chemically enhanced radiotherapy: visions for the futureRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsImproving the efficacy of chemoradiation with targeted agentsEmerging treatment options for nasopharyngeal carcinomaTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabModeling nasopharyngeal carcinoma in three dimensionsIs pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.Treatment of nasopharyngeal carcinoma with pulmonary tuberculosis and gout: A case report.Adding maximum standard uptake value of primary lesion and lymph nodes in 18F-fluorodeoxyglucose PET helps predict distant metastasis in patients with nasopharyngeal carcinoma.Interaction of radiation therapy with molecular targeted agentsOral epithelial stem cells - implications in normal development and cancer metastasis.Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients.Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective studyImpact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinomaEvaluation of the dosimetric feasibility of hippocampal sparing intensity-modulated radiotherapy in patients with locally advanced nasopharyngeal carcinoma.The impact of reduced-volume, intensity-modulated radiation therapy on disease control in nasopharyngeal carcinoma.Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinomaInvestigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysisCorrelation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusionInduction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.The Globalization of Cooperative Groups.Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinomaCurrent and emerging treatment options for nasopharyngeal carcinoma.Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy.Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivoA Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.Patterns of failure after the reduced volume approach for elective nodal irradiation in nasopharyngeal carcinomaPlasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma.Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation.The feasibility of omitting irradiation to the contralateral lower neck in stage N1 nasopharyngeal carcinoma patients.An elective radiation dose of 46 Gy is feasible in nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: A long-term follow-up result.
P2860
Q26767175-A520D5E8-37AE-4D22-9843-825A6EFB0E71Q26779221-2C9FBE22-6AF1-4580-90FF-58515A474922Q26850193-38B49C3B-3294-4C22-868B-00372C720666Q26995560-4EE1F070-76E1-4C97-94A6-52E295AE3B43Q27016002-F2011CA4-EC6A-4AF0-8DD8-4A6B60EA2A8EQ30846827-E233E839-7184-4945-AC8C-569FC40D4C43Q33418562-0BD83B18-9D0C-4B53-8E2F-BBBF0B2CEDCEQ33599243-2AA89945-A5BE-4BF8-8BCF-136EC53ABF2BQ33702316-6D13C0F3-FD87-4AD8-8B26-73BBCE2C6E5BQ33705268-A8573ECB-2817-432E-A352-3D7FF10E3B3CQ33771373-F9061599-4FE8-47C9-B06E-5A34EC4B0F44Q33802617-C974C77C-F03D-4BB1-A4FA-4D8766F843DFQ33844028-DB01F8D7-112B-4E9E-8978-EFDDA7E927E1Q33961339-55C4E23F-6F5A-4BC4-9BF8-3F7DC635AEEBQ34124285-DEB0A875-79F4-4ADE-8E37-9019933D1262Q34147649-F17ADBC2-66C1-4A38-9872-882134A1F596Q34566972-ABA7A6E9-B1B4-4720-8A33-26B5BF924386Q35030360-008878F6-34B2-4F77-AA9C-561DEFF65B29Q35087399-F953B656-6A39-4917-AE37-33E558D5449EQ35108557-A7AC383A-4BC1-45EA-9FBF-CF0FE1D4726AQ35547568-21FD81D9-2222-4247-9D1B-7555A8661E48Q35694417-1230CD2D-50CB-47DF-892A-01D04FEA44C5Q35809636-144ED9E3-0F93-41A8-B180-9C891ABE9535Q36061130-0E299562-06C8-4262-AFA6-3144209E6B03Q36086448-B3443477-D334-4CFB-8552-5947A8D7F361Q36117722-16827A2B-8643-487F-AA92-741303A2958DQ36119749-F07384E8-7207-47BE-9D14-6525A787B8FBQ36121338-01361EAF-503A-4B2A-A897-7F23FD270080Q36359374-4A24D979-1534-4A2B-AD0E-365A872A536AQ36626509-9D73E42C-7B44-4697-82E1-784FCFCB2E5DQ36629614-D01CEDAE-C3AB-4211-B97F-D0CE8A219FD1Q36685556-8F601D23-5F07-47D3-976B-846BCDA6D015Q36710062-94291D15-DA92-47A7-BDD7-7E936900791CQ36727111-FEF03A59-A620-4A2A-ABA6-A7A01D88E30DQ36798856-82D043E4-1603-4956-A7B2-2F74B3F1F082Q36905882-CB321E60-4C0D-4783-8C73-E4ABD7F05C7DQ37156590-FABC882E-F90A-470A-8310-36F1E64FA276Q37183618-41EAC1BB-52C9-41B3-8876-E3C686E71358Q37370639-5567765A-6774-4BA7-9E46-94197B1225E0Q37646625-429433D4-6C8D-4F68-B522-259343843CEE
P2860
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Addition of bevacizumab to sta ...... e 2 multi-institutional trial.
@en
Addition of bevacizumab to sta ...... anced nasopharyngeal carcinoma
@nl
type
label
Addition of bevacizumab to sta ...... e 2 multi-institutional trial.
@en
Addition of bevacizumab to sta ...... anced nasopharyngeal carcinoma
@nl
prefLabel
Addition of bevacizumab to sta ...... e 2 multi-institutional trial.
@en
Addition of bevacizumab to sta ...... anced nasopharyngeal carcinoma
@nl
P2093
P2860
P921
P1433
P1476
Addition of bevacizumab to sta ...... se 2 multi-institutional trial
@en
P2093
A Dimitrios Colevas
Adam S Garden
Bonnie S Glisson
David G Pfister
K Kian Ang
Kenneth Hu
Nancy Y Lee
Qiang Zhang
Quynh T Le
P2860
P304
P356
10.1016/S1470-2045(11)70303-5
P577
2011-12-15T00:00:00Z